Kaleido Biosciences Valuation
| KLDODelisted Stock | USD 0.01 0.00 0.00% |
Kaleido Biosciences seems to be overvalued based on Macroaxis valuation methodology. Our model forecasts the value of Kaleido Biosciences from analyzing the firm fundamentals such as Shares Outstanding of 42.62 M, return on equity of -5.81, and Operating Margin of (79.28) % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Kaleido Biosciences' price fluctuation is very steady at this time. Calculation of the real value of Kaleido Biosciences is based on 3 months time horizon. Increasing Kaleido Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Kaleido Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Kaleido Pink Sheet. However, Kaleido Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.01 | Real 0.006418 | Hype 0.01 |
The intrinsic value of Kaleido Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Kaleido Biosciences' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Kaleido Biosciences helps investors to forecast how Kaleido pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Kaleido Biosciences more accurately as focusing exclusively on Kaleido Biosciences' fundamentals will not take into account other important factors: Kaleido Biosciences Total Value Analysis
Kaleido Biosciences is now forecasted to have valuation of (16.73 M) with market capitalization of 421.96 K, debt of 5.55 M, and cash on hands of 38.47 M. The negative valuation of Kaleido Biosciences may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Kaleido Biosciences fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(16.73 M) | 421.96 K | 5.55 M | 38.47 M |
Kaleido Biosciences Investor Information
The company has price-to-book ratio of 0.0. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Kaleido Biosciences recorded a loss per share of 2.16. The entity had not issued any dividends in recent years. Based on the key indicators related to Kaleido Biosciences' liquidity, profitability, solvency, and operating efficiency, Kaleido Biosciences is not in a good financial situation at this time. It has a very high probability of going through financial hardship in February.Kaleido Biosciences Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Kaleido Biosciences has an asset utilization ratio of 2.2 percent. This suggests that the Company is making $0.022 for each dollar of assets. An increasing asset utilization means that Kaleido Biosciences is more efficient with each dollar of assets it utilizes for everyday operations.Kaleido Biosciences Ownership Allocation
Kaleido Biosciences maintains a total of 42.62 Million outstanding shares. Roughly 98.91 % of Kaleido Biosciences outstanding shares are held by general public with 0.73 pct. owned by insiders and only 0.36 % by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Kaleido Biosciences Profitability Analysis
The company reported the previous year's revenue of 1.1 M. Net Loss for the year was (90.29 M) with loss before overhead, payroll, taxes, and interest of (66.7 M).About Kaleido Biosciences Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Kaleido Biosciences. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Kaleido Biosciences based exclusively on its fundamental and basic technical indicators. By analyzing Kaleido Biosciences's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Kaleido Biosciences's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Kaleido Biosciences. We calculate exposure to Kaleido Biosciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Kaleido Biosciences's related companies.Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Kaleido Biosciences operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 76 people.
8 Steps to conduct Kaleido Biosciences' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Kaleido Biosciences' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Kaleido Biosciences' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Kaleido Biosciences' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Kaleido Biosciences' revenue streams: Identify Kaleido Biosciences' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Kaleido Biosciences' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Kaleido Biosciences' growth potential: Evaluate Kaleido Biosciences' management, business model, and growth potential.
- Determine Kaleido Biosciences' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Kaleido Biosciences' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Kaleido Biosciences Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 33.5 M | |
| Retained Earnings | -364.5 M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Other Consideration for investing in Kaleido Pink Sheet
If you are still planning to invest in Kaleido Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kaleido Biosciences' history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |